Editorial Archives - Page 100 of 122 - ExecEdge

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license...

First Watch Restaurant Group Shares Climb on New Guidance

First Watch Restaurant Group Shares Climb on New Guidance

By Exec Edge Editorial Staff First Watch Restaurant Group, Inc. (Nasdaq: FWRG) shares rose 3 percent after the company raised guidance for 2023. The daytime dining chain raised its 2023 adjusted EBITDA guidance, projecting total revenue growth of 16% to...

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

By Exec Edge Editorial Staff SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes. SAB-185 demonstrated benefit in...

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

By Exec Edge Editorial Staff FullBeauty will acquire plus-size fashion authority ELOQUII Inc. from Walmart, it said in a statement. The acquisition will allow FullBeauty to expand its presence in the $81 billion women’s plus-sized sector in the U.S. ELOQUII...

Input your search keywords and press Enter.